2012
DOI: 10.1186/cc11145
|View full text |Cite
|
Sign up to set email alerts
|

Clinical utility of biomarkers of endothelial activation in sepsis-a systematic review

Abstract: IntroductionA strong biologic rationale exists for targeting markers of endothelial cell (EC) activation as clinically informative biomarkers to improve diagnosis, prognostic evaluation or risk-stratification of patients with sepsis.MethodsThe objective was to review the literature on the use of markers of EC activation as prognostic biomarkers in sepsis. MEDLINE was searched for publications using the keyword 'sepsis' and any of the identified endothelial-derived biomarkers in any searchable field. All clinic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
104
0
4

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 122 publications
(117 citation statements)
references
References 94 publications
(234 reference statements)
3
104
0
4
Order By: Relevance
“…Our results demonstrate that hemostasis-related parameters have a significant impact on severity and outcome prediction of patients with sepsis, since endothelial and coagulation dysfunction is essential in pathophysiology of sepsis (19)(20)(21).…”
Section: Discussionmentioning
confidence: 94%
“…Our results demonstrate that hemostasis-related parameters have a significant impact on severity and outcome prediction of patients with sepsis, since endothelial and coagulation dysfunction is essential in pathophysiology of sepsis (19)(20)(21).…”
Section: Discussionmentioning
confidence: 94%
“…Recently, a meta-analysis [23] revealed three studies that showed ADAMTS13 was significantly lower in sepsis than other critically ill non-septic patients [14,19,24].…”
Section: Discussionmentioning
confidence: 99%
“…These include regulators of endothelial activation, vWF and ADAMTS13 [9]. In 1996, a protease that was able to cleave VWF [10,11]was described and, in 2001, Zheng et al [12] named this protease ADAMTS13 (the 13th member of A Disintegrin-like And Metalloprotease with ThromboSpondin type 1 motif, member 13).…”
mentioning
confidence: 99%
“…We chose to focus on the vascular effector proteins, VEGF, VCAM-1, and endostatin (Fig. 2), since vascular endothelial inflammation is a key feature of MOF syndromes (20,23,40). Protein levels of VEGF were found to be significantly elevated in both VILI and CLPϩVILI compared with sham (P Ͻ 0.001 and P Ͻ 0.05, respectively) and CLP kidneys (P Ͻ 0.001 and P Ͻ 0.01, respectively) by Western blot analysis.…”
Section: Mediators Of Vascular Endothelial Inflammation Are Increasedmentioning
confidence: 99%